Targeting triple-negative breast cancer using cord-blood CD34⁺ HSPC-derived mesothelin-specific CAR-NKT cells with potent antitumor activity

By afschroeder • October 13, 2025

Li YR, Shen X, Zhu Y, Li Z, Hon R, Tian Y, Huang J, Zhao AS, Ma NY, Zhang C, Lin D, Sargsyan K, Yuan Y, Yang L. Targeting triple-negative breast cancer using cord-blood CD34⁺ HSPC-derived mesothelin-specific CAR-NKT cells with potent antitumor activity. J Hematol Oncol. 2025 Oct 13;18(1):86. doi: 10.1186/s13045-025-01736-9. PMID: 41077583.

Tags: allogeneic CAR-NKT cells, Allogeneic cell therapy, allorejection, Cedars Sinai DoM, CRISPR-Cas9 gene editing, Hematology/Oncology, HLA ablation, Mesothelin-targeting CAR (MCAR), Metastatic model, Multiple tumor targeting mechanism, Off-the-shelf, Orthotopic model, Potent antitumor activity, Publications, Triple-negative breast cancer (TNBC), tumor microenvironment (TME), Tumor-associated macrophage (TAM)

A Multi-Analyte cfDNA-based Blood Test for Early Detection of Hepatocellular Carcinoma

Taggart DJ, Mahajan S, Gallant MA, Pinkoviezky I, Xu J, Sorg AJ, Roberts CC, Slinkov D, Gorospe EC, Mubarak A, Bhandari BR, Freilich B, Gunn[...]

The Epidemiology of Young-Onset Barrett’s Esophagus in the United States: A National Population-Based Study Using the TriNetX Database

Vasireddy AR, Chandar AK, Maravillas MA, Perez JA, Algarin Perneth SL, Kolb JM, Leggett CL, Katzka DA, Iyer PG, Gaddam S, Kamboj AK. The Epidemiology[...]

Activation of the impaired NAMPT/SIRT7/SOD2 axis restores alveolar progenitor renewal in idiopathic pulmonary fibrosis

Zhang X, Liu X, Qiao Y, Rabata A, Liu N, Yao C, Parimon T, Chen D, Hogaboam CM, Chen P, Stripp BR, Gardell SJ, Jiang[...]